Furthermore, it downregulated the apoptotic executor, active caspase-3.<h4>Conclusions</h4>The CJO NEs have shown strong promise in lowering obesity-induced hepatic steatosis and mitigating cardiac and pancreatic injury via hypoglycemic, antidyslipidemic, cytoprotective, antioxidant, and antiapoptotic activities. Here, CASP3 is linked to obesity due to melanocortin 4 receptor deficiency.